GL1X · GenesisL1 explorer

Research workbench

The FK1 domain of FKBP51 in complex with (2R,5S,12R)-12-cyclohexyl-2- [2-(3,4-DIMETHOXYPHENYL)ETHYL]-15,15,16-trimethyl-3,19-dioxa-10,13, 16-TRIAZATRICYCLO[18.3.1.0^5,^10]TETRACOSA-1(24),20,22-triene-4,11, 14,17-tetrone

Analyse The FK1 domain of FKBP51 in complex with (2R,5S,12R)-12-cyclohexyl-2… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
7AWF
Type
protein
Length
127 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Peptidyl-prolyl cis-trans isomerase FKBP5
EC
5.2.1.8
UniProt
Q13451
Ligands
S8N
Pockets
1 · best druggability 0.49

Structure

x-ray diffraction · 1 distinct chain · 14% helix, 33% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
APeptidyl-prolyl cis-trans isomerase FKBP5 (EC 5.2.1.8)protein12714% helix, 33% strandQ13451

Ligands and binding sites

  • S8N · (2~{R},5~{S},12~{R})-12-cyclohexyl-2-[2-(3,4-dimethoxyphenyl)ethyl]-15,15,16-trimethyl-3,19-dioxa-10,13,16-triazatricyclo[18.3.1.0^{5,10}]tetracosa-1(24),20,22-triene-4,11,14,17-tetrone · ligand · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

1 pocket found on a 1 Å grid, 0 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
11460.490.7820S8N

Compared structures

  • 7AWF · The Fk1 domain of FKBP51 in complex with (2R,5S,12R)-12-cyclohexyl-2-[2-(3,4-dimethoxyphen… · the same entry in another collection · chain A against A, TM-score 1.00
  • Q13451 · AlphaFold monomer V2.0 prediction for peptidyl-prolyl cis-trans isomerase FKBP5 (Q13451) · a predicted model of the same protein · chain A against A, TM-score 0.95

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.